Universiteit Maastricht

PRESS RELEASE


 VitaK acquired ISO-9001 certification click

Dietary vitamin K2 intake found to be inversely related to cancer risk click
Vitamin K in Daily Mail click


Vitamin K may reverse arterial calcification - study click


New Human Study Shows Vitamin K2 Superior to Vitamin K1 click


Vitamin K May Help Clear Arteries click


Vitamin K2 protects against heart attacks.click


Vitamin K may reverse artery hardening, suggests study click


Anouncement Alliance Vitak NattoPharma click


Vitamin K supplements could improve anti-blood clot control click


New Patent-pending Indications for Natural Vitamin K2
Announced by PL Thomas in Strategic Alliance with Natto Pharma and VitaK BV

2006/09/20 - P. L. Thomas

PL Thomas & Company (PLT) of Morristown, NJ today announced new patent-pending indications for its Natural Vitamin K2 marketed under the trademark MenaQ7™.
The role of Natural Vitamin K2 in bone health is well established, and recent research has shown that of the group of K vitamins, only K2 is linked to cardiovascular health. The alliance between PLT, Natto Pharma, Norway and VitaK BV now allows MenaQ7 to be offered for cardiovascular benefits with proprietary research and US patents pending.

PLT is the exclusive North American representative for Natto Pharma, Norway, the supplier of MenaQ7. Natto Pharma, as part of the Strategic Alliance, has acquired three US patents pending from VitaK, which is closely associated with the Cardiovascular Research Institute, University of Maastricht, The Netherlands. Further, Natto Pharma has committed to a five-year, multimillion dollar research initiative with VitaK, whereby the proprietary research and subsequent intellectual property developed will be owned by Natto Pharma.

read the full article (pdf)